China State Institute of Pharmaceutical Industry (hereinafter short for CSIPI) was originated from Shanghai Institute of Pharmaceutical Industry which was founded in 1957.
Shanghai Institute of Pharmaceutical Industry used to be the scientific research and technology innovation base in our pharmaceutical industry. In 2000, it was listed in central enterprises and was subordinated to State-Owned Assets Supervision and Administration Commission of the State Council (SASAC).
In April 2010, according to the requirement of “building a central enterprise healthcare industry platform” presented by SASAC, Shanghai Institute of Pharmaceutical Industry, Sinopharm Group and China National Biotic Group were recombined and the new Sinopharm was formed.
In November 2010, Sinopharm Board of Directors decided to establish China State Institute of Pharmaceutical Industry on the base of Shanghai Institute of Pharmaceutical Industry and Sichuan Industrial Institute of Antibiotics.
CSIPI is the leader with its science research and contribution among all pharmaceutical application-bases research institute in our country. It is one of the technology innovation bases in pharmaceutical industry.
Today, more than 30 listed companies in pharmaceutical section of Shanghai and Shenzhen Stock market sell products mainly output by CSIPI.
Among the six Enterprises Innovation New Drug Incubating Bases approved first in “Eleventh Five-Year” New Drug Projects, four are supported by the products from CSIPI.